Last reviewed · How we verify

Famtozinameran 12 Years of age and older (famtozinameran-12-years-of-age-and-older)

Pfizer · FDA-approved active Vaccine Quality 42/100

Famtozinameran 12 Years of age and older (generic name: famtozinameran-12-years-of-age-and-older) is a monoclonal antibody Vaccine drug developed by Pfizer. It is currently FDA-approved for COVID-19 prevention, COVID-19 treatment.

Famtozinameran works by targeting the SARS-CoV-2 virus.

Famtozinameran 12 Years of age and older, developed by Pfizer, holds a significant market position as the world's best-selling drug with revenues of $4367M. Its competitive advantage lies in its combination with Tozinameran and Riltozinameran, offering broad protection against multiple variants including BA.1 and BA.4-5. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its accessibility and market reach. The pipeline outlook remains robust, with no ongoing clinical trials but a strong foundation in existing approved indications and combination therapies.

At a glance

Generic namefamtozinameran-12-years-of-age-and-older
SponsorPfizer
Drug classmonoclonal antibody
TargetSARS-CoV-2 virus
ModalityVaccine
Therapeutic areaInfectious Disease
PhaseFDA-approved
Annual revenue4367

Mechanism of action

Famtozinameran is a drug designed to prevent and treat COVID-19. It targets the SARS-CoV-2 virus, which causes the disease. By targeting this virus, famtozinameran can help prevent and treat COVID-19. This mechanism of action is crucial in understanding how the drug works and its potential benefits.

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Famtozinameran 12 Years of age and older

What is Famtozinameran 12 Years of age and older?

Famtozinameran 12 Years of age and older (famtozinameran-12-years-of-age-and-older) is a monoclonal antibody drug developed by Pfizer, indicated for COVID-19 prevention, COVID-19 treatment.

How does Famtozinameran 12 Years of age and older work?

Famtozinameran works by targeting the SARS-CoV-2 virus.

What is Famtozinameran 12 Years of age and older used for?

Famtozinameran 12 Years of age and older is indicated for COVID-19 prevention, COVID-19 treatment.

Who makes Famtozinameran 12 Years of age and older?

Famtozinameran 12 Years of age and older is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Famtozinameran 12 Years of age and older?

famtozinameran-12-years-of-age-and-older is the generic (nonproprietary) name of Famtozinameran 12 Years of age and older.

What drug class is Famtozinameran 12 Years of age and older in?

Famtozinameran 12 Years of age and older belongs to the monoclonal antibody class. See all monoclonal antibody drugs at /class/monoclonal-antibody.

What development phase is Famtozinameran 12 Years of age and older in?

Famtozinameran 12 Years of age and older is FDA-approved (marketed).

What is Famtozinameran 12 Years of age and older's annual revenue?

Famtozinameran 12 Years of age and older generated approximately $0.0B in annual revenue.

What does Famtozinameran 12 Years of age and older target?

Famtozinameran 12 Years of age and older targets SARS-CoV-2 virus and is a monoclonal antibody.

Related